Author

Janelle Meyer

OpenAlex ID: A5114213873

Optimizing Clinical Trial Subject Selection: Insights from Exigent Research Network and the Tempus AI TIME Program Collaboration

2024 · Samantha Mallahan, Ajeet Gajra, et al. · AI in Precision Oncology · 6

Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine

2023 · Guillermo Garcia-Manero, James McCloskey, et al. · Blood · 4

Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)

2024 · Guillermo Garcia-Manero, James McCloskey, et al. · Blood · 3

523: Circulating Tumor Dna for Detection of Molecular Residual Disease (mrd) in Patients (pts) With Stage Ii/iii Colorectal Cancer (crc): Final Analysis of the Bespoke Crc Sub Cohort

2025 · Kim Magee, Purvi Shah, et al. · Gastroenterology

MDS-773 Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine

2024 · Guillermo Garcia-Manero, James McCloskey, et al. · Clinical Lymphoma Myeloma & Leukemia

Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine

2024 · Guillermo Garcia-Manero, James McCloskey, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 6

Citation count: 13

H-index: 3

I10-index: